More importantly, new mouse evidence has pointed to a role for selective SHP2 inhibition in myeloid cells that may inhibit tumorogenesis independently of the PD-1 inhibition pathway, thereby implicating SHP2’s immunoregulatory functions extend beyond classical checkpoint pathways, and reaffirms the rationale for further pursue pharmacological inhibition both in the context of cancer and inflammatory/oxidative stress conditions [5]. Here, RPL17 is linked to cancer.